HFrEF

AcronymDefinition
HFrEFHeart Failure with Reduced Ejection Fraction (cardiology)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
demonstrated that higher concentrations of ET-1 were associated with worse LV diastolic performance and worse clinical outcomes in patients with HFrEF (49).
Thus, there is the "grey zone" in diagnosing HFrEF with LVEF of 45 to 50% or 45 to 55%.
Desai, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues randomly assigned patients with HFrEF to either sacubitril-valsartan (231 patients) or enalapril (233 patients) for 12 weeks.
Release date- 02092019 - Basel - Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with heart failure with reduced ejection fraction (HFrEF).
EMPEROR-Preserved has randomized 4,126 patients with HFpEF to empagliflozin (Jardiance) or placebo, while EMPEROR-Reduced has 2,850 patients with heart failure with reduced ejection fraction (HFrEF).
Heart failure with reduced ejection fraction (HFrEF) is clinical syndrome with distinctive symptoms and signs caused by a cardiac abnormality.
For this study, 50 patients with heart failure with reduced ejection fraction (HFrEF; left ventricular ejection fraction <40%) who met the pre-specified inclusion and exclusion criteria were chosen.
Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes.